{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T20:24:52Z","timestamp":1784492692096,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Clinical manifestations of sarcoidosis vary widely, depending on the intensity of the inflammation and the organ systems affected. So far, no curative treatment exists; the disease can only be suppressed. All treatment options cause side effects affecting quality of life. The aim of this study was to establish and rank the prevalence of self-reported gastrointestinal side effects of drugs used in the treatment of sarcoidosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross-sectional web-based anonymous survey about complaints and side effects was conducted among sarcoidosis patients in the Netherlands, United Kingdom, and United States of America.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the participants, 70% were being treated with one or more drugs. The most important reported side effect was weight gain, associated with increased appetite among prednisone users (as monotherapy as well as in combination with other drugs). Methotrexate (MTX) users especially experienced nausea, with monotherapy as well as combination therapy. Vomiting and weight loss were most prominent among azathioprine and mycophenolate mofetil (MMF) users, whereas diarrhoea was frequently mentioned by MMF and MTX users. The reported side effects of hydroxychloroquine were generally rather mild.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The current study ranked the gastrointestinal side effects associated with pharmacotherapy in sarcoidosis patients. Pharmacotherapy does have multiple gastrointestinal side effects. The strongest association between a reported side effect and drug use was that of weight gain associated with increased appetite among prednisone users. It would therefore be useful for future research to look further into dietary interventions to counter these side effects and reduce their burden.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00408-020-00323-8","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T06:02:42Z","timestamp":1579500162000},"page":"395-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-0110","authenticated-orcid":false,"given":"M.","family":"Drent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. L. J.","family":"Proesmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D. P.","family":"Elfferich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. T.","family":"Jessurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M. G.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. M.","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. D. O.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"issue":"1","key":"323_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","volume":"5","author":"J Grunewald","year":"2019","unstructured":"Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Muller-Quernheim J (2019) Sarcoidosis. Nat Rev Dis Primers 5(1):45","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"323_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ccm.2015.08.013","volume":"36","author":"M Drent","year":"2015","unstructured":"Drent M, Strookappe B, Hoitsma E, De Vries J (2015) Consequences of sarcoidosis. Clin Chest Med 36(4):727\u2013737","journal-title":"Clin Chest Med"},{"issue":"5","key":"323_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","volume":"19","author":"JP Cremers","year":"2013","unstructured":"Cremers JP, Drent M, Bast A, Shigemitsu H, Baughman RP, Valeyre D, Sweiss NJ, Jansen TL (2013) Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 19(5):545\u2013561","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"323_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1378\/chest.12-1728","volume":"144","author":"ADM Vorselaars","year":"2013","unstructured":"Vorselaars ADM, Wuyts WA, Vorselaars VMM et al (2013) Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 144(3):805\u2013812","journal-title":"Chest"},{"issue":"2","key":"323_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/CPM.0000000000000136","volume":"23","author":"P Korsten","year":"2016","unstructured":"Korsten P, Strohmayer K, Baughman RP, Sweiss NJ (2016) Refractory pulmonary sarcoidosis\u2014proposal of a definition and recommendations for the diagnostic and therapeutic approach. Clin Pulm Med 23(2):67\u201375","journal-title":"Clin Pulm Med"},{"issue":"10","key":"323_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","volume":"3","author":"RP Baughman","year":"2015","unstructured":"Baughman RP, Grutters JC (2015) New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med 3(10):813\u2013822","journal-title":"Lancet Respir Med"},{"issue":"6","key":"323_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2174\/18715281113126660062","volume":"12","author":"AD Vorselaars","year":"2013","unstructured":"Vorselaars AD, van Moorsel CH, Deneer VH, Grutters JC (2013) Current therapy in sarcoidosis, the role of existing drugs and future medicine. Inflamm Allergy Drug Targets 12(6):369\u2013377","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"10","key":"323_CR8","first-page":"1906","volume":"31","author":"GW Cannon","year":"2004","unstructured":"Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P (2004) Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 31(10):1906\u20131911","journal-title":"J Rheumatol"},{"issue":"11","key":"323_CR9","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","volume":"108","author":"N Hamzeh","year":"2014","unstructured":"Hamzeh N, Voelker A, Forssen A, Gottschall EB, Rose C, Mroz P, Maier LA (2014) Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med 108(11):1663\u20131669","journal-title":"Respir Med"},{"issue":"24","key":"323_CR10","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","volume":"87","author":"S Bitoun","year":"2016","unstructured":"Bitoun S, Bouvry D, Borie R et al (2016) Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology 87(24):2517\u20132521","journal-title":"Neurology"},{"issue":"3","key":"323_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.clindermatol.2007.03.011","volume":"25","author":"RP Baughman","year":"2007","unstructured":"Baughman RP, Lower EE (2007) Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 25(3):334\u2013340","journal-title":"Clin Dermatol"},{"issue":"2","key":"323_CR12","first-page":"113","volume":"30","author":"RP Baughman","year":"2013","unstructured":"Baughman RP, Janovcik J, Ray M, Sweiss N, Lower EE (2013) Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 30(2):113\u2013120","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"323_CR13","first-page":"91","volume":"31","author":"M Drent","year":"2014","unstructured":"Drent M, Cremers JP, Jansen TL, Baughman RP (2014) Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 31(2):91\u2013107","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"7","key":"323_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","volume":"11","author":"WE James","year":"2018","unstructured":"James WE, Baughman R (2018) Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol 11(7):677\u2013687","journal-title":"Expert Rev Clin Pharmacol"},{"key":"323_CR15","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","volume":"138","author":"MC Schimmelpennink","year":"2018","unstructured":"Schimmelpennink MC, Vorselaars ADM, van Beek FT, Crommelin HA, Deneer VHM, Keijsers RGM, Veltkamp M (2018) Efficacy and safety of infliximab biosimilar Inflectra\u00ae in severe sarcoidosis. Respir Med 138:S7\u2013S13","journal-title":"Respir Med"},{"issue":"2","key":"323_CR16","first-page":"356","volume":"35","author":"D Merinopoulos","year":"2017","unstructured":"Merinopoulos D, Hayes F, Gallagher DA, Dasgupta B (2017) A case report of neurosarcoidosis successfully treated with an infliximab biosimilar after a relapse while on dual therapy. Clin Exp Rheumatol 35(2):356\u2013357","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"323_CR17","first-page":"280","volume":"32","author":"M Veltkamp","year":"2016","unstructured":"Veltkamp M, Drent M, Baughman RP (2016) Infliximab or biosimilars in sarcoidosis; to switch or not to switch? Sarcoidosis Vasc Diffuse Lung Dis 32(4):280\u2013283","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"323_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jpm9020023","volume":"9","author":"CC Moor","year":"2019","unstructured":"Moor CC, Gur-Demirel Y, Wijsenbeek MS (2019) Feasibility of a comprehensive home monitoring program for sarcoidosis. J Pers Med 9(2):23","journal-title":"J Pers Med"},{"issue":"5","key":"323_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/MCP.0000000000000602","volume":"25","author":"SJ van Helmondt","year":"2019","unstructured":"van Helmondt SJ, Polish LB, Judson MA, Grutters JC (2019) Patient perspectives in sarcoidosis. Curr Opin Pulm Med 25(5):478\u2013483","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"323_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","volume":"136","author":"AA van Everdingen","year":"2002","unstructured":"van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136(1):1\u201312","journal-title":"Ann Intern Med"},{"key":"323_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","volume":"132","author":"NA Khan","year":"2017","unstructured":"Khan NA, Donatelli CV, Tonelli AR, Wiesen J, Ribeiro Neto ML, Sahoo D, Culver DA (2017) Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med 132:9\u201314","journal-title":"Respir Med"},{"issue":"3","key":"323_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nutres.2013.12.006","volume":"34","author":"BS Berthon","year":"2014","unstructured":"Berthon BS, MacDonald-Wicks LK, Wood LG (2014) A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans. Nutr Res 34(3):179\u2013190","journal-title":"Nutr Res"},{"issue":"4","key":"323_CR23","first-page":"289","volume":"30","author":"JP Cremers","year":"2013","unstructured":"Cremers JP, Drent M, Elfferich MD, Nelemans PJ, Wijnen PA, Witteman BJ, Schols AM (2013) Body composition profiling in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 30(4):289\u2013299","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"5","key":"323_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/MCP.0000000000000503","volume":"24","author":"YC Cozier","year":"2018","unstructured":"Cozier YC, Govender P, Berman JS (2018) Obesity and sarcoidosis: consequence or contributor? Curr Opin Pulm Med 24(5):487\u2013494","journal-title":"Curr Opin Pulm Med"},{"key":"323_CR25","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.rmed.2017.10.022","volume":"138","author":"CE Broos","year":"2018","unstructured":"Broos CE, Poell LHC, Looman CWN et al (2018) No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respir Med 138:S31\u2013S37","journal-title":"Respir Med"},{"key":"323_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.phrs.2013.11.004","volume":"79","author":"EJ Ruijters","year":"2014","unstructured":"Ruijters EJ, Haenen GR, Weseler AR, Bast A (2014) The cocoa flavanol (-)-epicatechin protects the cortisol response. Pharmacol Res 79:28\u201333","journal-title":"Pharmacol Res"},{"issue":"5","key":"323_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/MCP.0000000000000501","volume":"24","author":"A Bast","year":"2018","unstructured":"Bast A, Semen KO, Drent M (2018) Nutrition and corticosteroids in the treatment of sarcoidosis. Curr Opin Pulm Med 24(5):479\u2013486","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"323_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.clnu.2011.01.010","volume":"30","author":"AW Boots","year":"2011","unstructured":"Boots AW, Drent M, de Boer VC, Bast A, Haenen GR (2011) Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr 30(4):506\u2013512","journal-title":"Clin Nutr"},{"issue":"7","key":"323_CR29","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/09637486.2017.1288199","volume":"68","author":"A de Boer","year":"2017","unstructured":"de Boer A, van de Worp W, Hageman GJ, Bast A (2017) The effect of dietary components on inflammatory lung diseases\u2014a literature review. Int J Food Sci Nutr 68(7):771\u2013787","journal-title":"Int J Food Sci Nutr"},{"issue":"8","key":"323_CR30","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/art.39647","volume":"68","author":"JF Baker","year":"2016","unstructured":"Baker JF, Sauer BC, Cannon GW et al (2016) Changes in body mass related to the initiation of disease-modifying therapies in rheumatoid arthritis. Arthritis Rheumatol 68(8):1818\u20131827","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"323_CR31","first-page":"60","volume":"17","author":"RP Baughman","year":"2000","unstructured":"Baughman RP, Winget DB, Lower EE (2000) Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 17(1):60\u201366","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"7","key":"323_CR32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/j.2326-5205.1989.tb00014.x","volume":"32","author":"G Singh","year":"1989","unstructured":"Singh G, Fries JF, Spitz P, Williams CA (1989) Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 32(7):837\u2013843","journal-title":"Arthritis Rheum"},{"issue":"7","key":"323_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"RP Baughman","year":"2006","unstructured":"Baughman RP, Drent M, Kavuru M et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174(7):795\u2013802","journal-title":"Am J Respir Crit Care Med"},{"key":"323_CR34","unstructured":"European Medicines Agency INN-Infliximab (2019) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_nl.pdf. Accessed 3 Dec 2019"},{"issue":"6","key":"323_CR35","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10067-016-3244-7","volume":"35","author":"P Sfriso","year":"2016","unstructured":"Sfriso P, Caso F, Filardo GS et al (2016) Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study. Clin Rheumatol 35(6):1615\u20131618","journal-title":"Clin Rheumatol"},{"key":"323_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/593039","author":"A Lutf","year":"2012","unstructured":"Lutf A, Hammoudeh M (2012) Weight gain and hair loss during anti-TNF therapy. Int J Rheumatol. https:\/\/doi.org\/10.1155\/2012\/593039","journal-title":"Int J Rheumatol"},{"issue":"6","key":"323_CR37","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1128\/AAC.02437-14","volume":"58","author":"E Angelakis","year":"2014","unstructured":"Angelakis E, Million M, Kankoe S, Lagier JC, Armougom F, Giorgi R, Raoult D (2014) Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. Antimicrob Agents Chemother 58(6):3342\u20133347","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"323_CR38","first-page":"315","volume":"156","author":"T Wang","year":"2017","unstructured":"Wang T, Glendinning J, Grushka M, Hummel T, Mansfield K (2017) From the cover: drug-induced taste disorders in clinical practice and preclinical safety evaluation. Toxicol Sci 156(2):315\u2013324","journal-title":"Toxicol Sci"},{"issue":"1","key":"323_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.wjorl.2018.02.005","volume":"4","author":"SS Schiffman","year":"2018","unstructured":"Schiffman SS (2018) Influence of medications on taste and smell. World J Otorhinolaryngol Head Neck Surg 4(1):84\u201391","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"issue":"3","key":"323_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00002018-200831030-00002","volume":"31","author":"RL Doty","year":"2008","unstructured":"Doty RL, Shah M, Bromley SM (2008) Drug-induced taste disorders. Drug Saf 31(3):199\u2013215","journal-title":"Drug Saf"},{"issue":"5","key":"323_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00408-019-00260-1","volume":"197","author":"VLJ Proesmans","year":"2019","unstructured":"Proesmans VLJ, Drent M, Elfferich MDP, Wijnen P, Jessurun NT, Bast A (2019) Self-reported gastrointestinal side effects of antifibrotic drugs in Dutch idiopathic pulmonary fibrosis patients. Lung 197(5):551\u2013558","journal-title":"Lung"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-020-00323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-020-00323-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-020-00323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:00:47Z","timestamp":1695636047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-020-00323-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1007\/s00408-020-00323-8","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"12 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In accordance with the Dutch Act on Human Subjects Medical Research, the Medical Ethics Committee of St. Antonius Hospital Nieuwegein waived formal approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}